Skip to main content
SpringerLink
Log in

Safety Profile of Gemcitabine, Fludarabine and Cladribine

  • Conference paper
Innovative Antimetabolites in Solid Tumours

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 45 Accesses

Abstract

Antimetabolites are extensively used to treat a variety of tumours. These agents substitute for structurally similar substrates and interfere with important biochemical reactions. The safety profile of recently developed compounds such as gemcitabine, fludarabine and cladribine is discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. O’Rourke T, Brown T, Havlin T et al: Phase I clinical trial of difluorodeoxycytidine (Ly188011) given as an intravenous bolus on five consecutive days. Proc Am Assoc Cancer Res 1989 (30):82 (abstr)

    Google Scholar 

  2. Poplin E, Redman B, Flaherty L et al: Difluorodeoxycytidine (dFdC): A phase I study. Proc Am Soc Oncol 1989 (30):282 (abstr)

    Google Scholar 

  3. Vermorken J, Guastalla JP, Hatty SR et al: Phase I study of gemcitabine using a once every 2 week schedule. Eur J Cancer 1994 (submitted)

    Google Scholar 

  4. Grindey GB, Hertel LW, Plunkett W: Cytotoxicity and antitumor effect of 2,2’-difluorodeoxycytidine (gemcitabine). Cancer Invest 1990 (2):313

    Article  Google Scholar 

  5. Abbruzzese JL, Grunewald R, Weeks EA et al: A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991 (9):491–498

    PubMed  CAS  Google Scholar 

  6. Anderson H, Lund B, Hansen H et al: Phase II study of gemcitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1991 (10):848 (abstr)

    Google Scholar 

  7. Abbruzzese JL, Pazdur R, Ajani J et al: A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1991 (10):456 (abstr)

    Google Scholar 

  8. Tonato M: Gemcitabine safety overview. Satellite symposium of the 7th European Conference on Clinical Oncology and Cancer Nursing. Jerusalem 1993 pp 14–16

    Google Scholar 

  9. Ely Lilly, data on file

    Google Scholar 

  10. Mertens WC, Eisenhauer EA, Moore M et al: Gemcitabine in advanced renal cell carcinoma. Ann Oncol 1993 (4):331–332

    PubMed  CAS  Google Scholar 

  11. Eisenhauer E, Cormier Y, Gregg R et al: Gemcitabine is active in patients with previously untreated extensive small cell lung cancer. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 1992 (11):309 (abstr)

    Google Scholar 

  12. Von Hoff DD: Phase I clinical trials with fludarabine phosphate. Sem Oncol 1990 (17 suppl 8):33–38

    Google Scholar 

  13. Hutton J J, Von Hoff DD, Kuhn J et al: Phase I clinical investigation of 9-ß-D-arabinofuranosyl-2- fluoroadenine 5’-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 1984 (44):4183–4186

    Google Scholar 

  14. Bolt DH, Von Hoff DD, Kuhn JG et al: Effects on human peripheral lymphocytes of in vivo administration of 9-ß-D-arabinofuranosyl-2-fluoroadenine- 5’-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 1984 (44):4661–4666

    Google Scholar 

  15. Chun HG, Leyland Jones BR, Caryk SM et al: Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986 (70): 1225–1228

    PubMed  CAS  Google Scholar 

  16. Hurst PG, Habib MP, Garewal H et al: Pulmonary toxicity associated with fludarabine monophosphate. Invest New Drugs 1987 (5):207–210

    Article  PubMed  CAS  Google Scholar 

  17. Cheson BD: Issues for the future. Development of fludarabine phosphate. Sem Oncol 1990 (17 suppl 8 ): 71–78

    Google Scholar 

  18. Cheson BD: New antimetabolites in the treatment of human malignancies. Sem Oncol 1992 (19):695–706

    CAS  Google Scholar 

  19. Ross SR, Me Tavish D, Faulds D: Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs 1993 (45):737–759

    Article  PubMed  CAS  Google Scholar 

  20. Keating MJ, Kantarjian H, Talpaz M et al: Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989 (74):19–25

    PubMed  CAS  Google Scholar 

  21. Keating MJ, Kantarjian H, O’Brien S et al: Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991 (9):44–49

    PubMed  CAS  Google Scholar 

  22. Leiby JM, Snider KM, Kraut EH et al: Phase II trial of 9-B-D-arabinofuranosyl-2-fluoroadenine-5’-mono- phosphate in non-Hodgkin’s lymphoma: prospective comparison of response with deoxycytidine kinase activity. Cancer Res 1987 (47): 2719–2722

    Google Scholar 

  23. Redman JR, Cabanillas F, Velasquez WS et al: Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992 (10):790–794

    PubMed  CAS  Google Scholar 

  24. Sanders C, Perez EA, Lawrence HJ: Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine. Correspondence. Am J Hematol 1992 (39):314–315

    Article  PubMed  CAS  Google Scholar 

  25. Wijermans, Proc Am Soc Hematol 1992, abstr 174

    Google Scholar 

  26. Anaissie E, Kontoyiannis DP, Kantarjian H et al: Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 1990 (117):466–469

    Google Scholar 

  27. Cervantes F, Saldago C, Montserrat E et al: Fludarabine for prolymphocyte leukemia and risk of interstitial pneumonitis. Lancet 1990 (336): 1130

    Article  PubMed  CAS  Google Scholar 

  28. Hurst PG, Habib MP, Garewal H et al: Pulmonary toxicity associated with fludarabine monophosphate. Invest New Drugs 1987 (5):207–210

    Article  PubMed  CAS  Google Scholar 

  29. Kane GC, McMichael AJ, Patrick H et al: Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate. Respir Med 1992 (86):261–263

    Article  PubMed  CAS  Google Scholar 

  30. List AF, Kummet TD, Adams JD et al: Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 1990 (89):388–390

    Article  PubMed  CAS  Google Scholar 

  31. Bastion Y, Coiffier B, Dumontet C et al: Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992 (3):171–173

    PubMed  CAS  Google Scholar 

  32. Tosti S, Caruso R, D’Adamo F et al: Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Haemat 1992 (65):238–239

    Article  CAS  Google Scholar 

  33. Merkel DE, Griffin NL, Kaga-Hallet K et al: Central nervous system toxicity of fludarabine. Cancer Treat Rep 1986 (70): 1449–1450

    PubMed  CAS  Google Scholar 

  34. Hocster HS, Kim K, Green MD et al: Activity of fludarabine in previously treated non-Hodgkin’s low- grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992 (10):28–32

    Google Scholar 

  35. Cohen RB, Abdallah JM, Gray JR et al: Reversible neurologic toxicity in patients treated with standard- dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 1993 (118):114–116

    PubMed  CAS  Google Scholar 

  36. Carson DA, Wasson DB, Beutler E et al: Antileukemic and immunosuppressive activity of 2- chloro-2’-deoxyadenosine. Proc Natl Acad Sci USA 1984 (81):2232–2236

    Article  PubMed  Google Scholar 

  37. Carson DA, Wasson DB, Lamon J et al: A potent new anti-lymphocyte agent: 2-chlorodeoxyadeno- sine. Blood 1982 (60 suppl 1 ): 161a

    Google Scholar 

  38. Beutler E, Piro LD, Savan A et al: 2-chlorodeoxy- adenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leukemia Lymphoma 1991 (5): 1–8

    Article  Google Scholar 

  39. Beutler E: Cladribine (2-chlorodeoxyadenosine). Lancet 1992 (340):952–956

    Article  PubMed  CAS  Google Scholar 

  40. Betticher DC, Fey MF, Von Rohr A et al: High incidence of infections after 2-chlorodeoxyadeno- sine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute leukemias. Ann Oncol 1994 (5):57–64

    PubMed  CAS  Google Scholar 

  41. Juliusson G, Liliemark J: High complete remission rate from 2-chloro-2’-deoxyadenosine in previously treated patients with B cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993 (11):679–689

    PubMed  CAS  Google Scholar 

  42. O’Brien S, Kantarjian H, Estey E et al: Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994 (330):319–322

    Article  PubMed  Google Scholar 

  43. Spielberger RT, Stock W, Larson RA: Lysteriosis after 2-chlorodeoxyadenosine treatment. Correspondence. N Engl J Med 1993 (328):813–814

    Article  PubMed  CAS  Google Scholar 

  44. Carson DA, Wasson DB, Teatle R et al: Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983 (62):737–743

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Oncologia Medica, Policlinico Monteluce, 06122, Perugia, Italy

    Maurizio Tonato & Anna Maria Mosconi

Authors
  1. Maurizio Tonato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Maria Mosconi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Divisione di Oncologia Medica, Istituto Europeo di Oncologia, via Ripamonti 435, 20141, Milano, Italy

    Matti S. Aapro

  2. Division d’Onco-Hématologie, Hôpital Cantonal Universitaire, 1211, Genève 14, Switzerland

    Matti S. Aapro

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Tonato, M., Mosconi, A.M. (1994). Safety Profile of Gemcitabine, Fludarabine and Cladribine. In: Aapro, M.S. (eds) Innovative Antimetabolites in Solid Tumours. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79200-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79200-7_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79202-1

  • Online ISBN: 978-3-642-79200-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation